3056-17-5 (司他夫定,Stavudine)

司他夫定;3'-脱氧-2',3'-双脱氢胸苷;3'-脱氧-2',3'-双脱氢胸甙;斯他夫定;2',3'-二脱氢-3'-脱氧胸苷;1.3-丁二烯酸甲酯;2',3'-Didehydro-3'-deoxythymidine 2',3'-二脱氢-3'-脱氧胸苷;二乙酰氨基乙酸乙二胺（新凝灵）;二乙酰氨乙酸乙二胺;二乙酰氨乙酸乙二胺 芷血宁 止血宝 新凝灵;司他夫定 EP标准品;司他夫定 USP标准品;司他夫定 技术转让;司他夫定,Stavudine;司他夫定标准品;司他夫定系统适应性 EP标准品;2',3'-二去氢-3'-去氧胸腺定;齐多呋定杂质A(EP) 标准品;司他夫定系统适用性用混合物;司他夫啶;司他呋啶;司他夫定系统适应性对照品;

Stavudine;2',3'-didehydro-3'-deoxythymidine;3'-deoxythymidin-2'-ene;3'-deoxy-2',3'-didehydrothymidine;Stavudine (d4T);d4T;Sanilvudine;1-(2,3-Dideoxy-Beta-D-Glycero-2-Pentenofuranosyl)Thymine;1-(2,3-Dideoxy-β-D-glycero-2-pentenofuranosyl)thymine;1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine;2',3'-Anhydrothymidine;2',3'-didehydro-3'-deoxythimidine;2',3'-dideoxy-2',3'-didehydrothymidine;2',3'-dideoxy-2',3'-didehydrothymine;Avostav;Stauvidine;Stavir;Stavudine SysteM Suitability Mixture;Virostav;ZERIT;1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-(1H,3H)-dione;2′,3′-Anhydrothymidine;2′,3′-Didehydro-3′-deoxythymidine;[ "" ];Zerit(TM);2',3' Didehydro 3' deoxythymidine;NCGC00023212-30;Stavudine 100 microg/mL in Acetonitrile;HMS2051O20;STV;MLS001077292;SMR000673569;CAS-3056-17-5;Zerit Xr;3056-17-5;CCG-100902;STAVUDINE [USP-RS];BDBM50013111;220020-60-0;BO9LE4QFZF;STAVUDINE (MART.);1-(cis-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;Sanilvudine (JAN);BMY 27857;D-4T;GTPL12678;HMS3428C07;3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor;STAVUDINE [USP MONOGRAPH];HMS3261C13;ZIDOVUDINE IMPURITY A [WHO-IP];STAVUDINE [WHO-IP];3''-deoxy-2''-thymidine;CHEMBL991;1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione;STAVUDINE [INN];D00445;NC00684;1-(2,3-dideoxy-beta-glycero-pent-2-enofuranosyl)thymine;Stavudinum;MLS000759504;1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine;NSC163661;2',3'-Anhydrothymidine; d4T;STAVUDINE [MART.];2'-Thymidinene, 3'-deoxy-;D3580;Q423984;Stavudinum [INN-Latin];STAVUDINE [USAN];STAVUDINE [MI];NCGC00023212-07;Stavudine, European Pharmacopoeia (EP) Reference Standard;C07312;STAVUDINE (D4T) [VANDF];SANILVUDINE [JAN];EU-0100336;BIDD:GT0082;DB00649;NSC-759897;STAVUDINE [ORANGE BOOK];NCGC00023212-12;D4T & GM-CSF;Didehydrodeoxythymidine;STAVUDINE [EMA EPAR];STAVUDINE (EP MONOGRAPH);2'',3''-dideoxy-2'',3''-didehydrothymidine;AC-5263;HMS3714N22;D 1413;1-[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione;UNII-BO9LE4QFZF;Stavudine [USAN:BAN:INN];cid_18283;STAVUDINE [HSDB];SR-01000075802;NCGC00258944-01;Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-;AKOS005622554;NC00152;NCGC00023212-10;1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;NS00002353;Estavudina [INN-Spanish];1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione;Tox21_500336;Stavudine- Bio-X;NCGC00023212-04;NCGC00023212-13;ZIDOVUDINE IMPURITY A [EP IMPURITY];NCGC00023212-09;MLS006011922;ddeTyd;1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2;MFCD00132921;BMY-27857;MLS000028546;HSDB 7338;HMS2234C10;Stavudine [USAN:USP:INN:BAN];Tox21_300583;AB00383018_18;DTXSID1023819;Q-201742;1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;STAVUDINE (USP-RS);ddeThd;BD164571;NCGC00254372-01;Lopac0_000336;NSC-163661;Stavudine (dt4);HMS3039O05;Tox21_110886;STAVUDINE [EP IMPURITY];NCGC00023212-14;BCP02952;MLS001424091;D 4T (nucleoside);1-(2,3-Dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)thymine;Tox21_201393;SDCCGSBI-0050324.P002;BMY27857;Thymidine, 2',3'-didehydro-3'-deoxy-;1-[(2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL]-5-METHYL-1,2,3,4-TETRAHYDROPYRIMIDINE-2,4-DIONE;HY-B0116;STAVUDINE (DT4) [VANDF];SR-01000075802-4;NCGC00023212-05;Stavudine for system suitability, European Pharmacopoeia (EP) Reference Standard;CS-1872;Stavudin;STAVUDINE (USP MONOGRAPH);SCHEMBL38661;NCGC00261021-01;Stavudine, United States Pharmacopeia (USP) Reference Standard;NCGC00023212-11;2',3'-didehydro-2',3'-dideoxythymidine;3'-Deoxy-2'-thymidinene;1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione;Pharmakon1600-01502339;cid_5155;LP00336;MLS001055348;Zerit (TN);Tox21_110886_1;STAVUDINUM [WHO-IP LATIN];DTXCID803819;1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (ddeThd);HMS3259L21;EN300-120634;1-((2R,5S)-5-Hydroxymethyl-2,5-dihydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione;Z1530425068;2',3'-Didehydro-3'-deoxythymidine, >=98% (TLC);3''-deoxy-2'',3''-didehydrothymidine;KS-1115;D 4T;2',3'-Didehydro-2',3'-dideoxythmidine;Zerut XR;2'',3''-didehydro-3''-deoxythymidine;3'-Deoxy-2',3'-didehydro-D-thymidine;Thymidine, 2',3'-didehydro-, 3'-deoxy-;NSC759897;NCGC00023212-25;Dideoxydidehydrothymidine;NCGC00023212-08;NCGC00023212-03;SMR000058350;Estavudina;Stavudine (USAN/INN);SR-01000075802-1;NSC 163661;D4TMBY-27857-3;STAVUDINE [WHO-DD];BRN 0618327;J-700246;STAVUDINE [EP MONOGRAPH];Opera_ID_1281;CHEBI:63581;Stavudine for system suitability;BRD-K93880783-001-26-6;STK801888;BBL033763;Zidovudine Related Compound A;Sanilvudine;3'-Deoxy-2',3'-didehydro-D-thymidine;2',3'-Didehydro-3'-deoxythymidine;HY-B0116R;ND07118;Stavudine - Bio-X trade mark;Stavudine (Standard);Sanilvudine;2',3'-Didehydro-2',3'-dideoxythymidine;3'-Deoxy-2',3'-didehydro-D-thymidine;2',3'-Didehydro-3'-deoxythymidine;

MFCD00132921

XNKLLVCARDGLGL-JGVFFNPUSA-N

1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

O1[C@H](CO)C=C[C@@H]1N1C(NC(C(C)=C1)=O)=O

2938901000

抗病毒药。其生物利用度较高,有望改善抗HIV感染的现状。

胸苷溶于无水吡啶,冰盐冷却下滴加甲磺酰氯,搅拌、过滤,真空干燥,得磺酰化粗品。粗品用90%乙醇重结晶,得精品。将上述磺酰化产物溶于****水溶液,回流。用盐酸中和,蒸去溶剂,残液加氯仿,滤除不溶物,蒸去氯仿,用乙酸、乙醇结晶,得。色固体的环氧物。用乙醇重结晶2次可得白色絮状固体。将该环氧物溶于二甲亚砜,加入叔丁醇钾,在室温下搅拌。用50%乙酸的乙醇溶液中和至pH=7。减压浓缩,得到的物质用热丙酮洗涤。洗液过滤后浓缩,再加乙醇,活性炭脱色,过滤。蒸出乙醇,加少量苯旋转蒸发至溶液出现浑浊,静置。析出的固体用乙醇-苯(1:5)重结晶,得白色粉状的司他夫定。

618327

MFCD00132921